Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland.
I M
IM
Collins
F
F
King
K
K
O'Byrne
D061067:Antibodies, Monoclonal, Humanized / Q000191:economics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000378:metabolism; D006801:Humans; D007494:Ireland; D019057:Quality-Adjusted Life Years; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000191:economics* / Q000378:metabolism; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human